Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.69 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.69 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.65 |
| ▸ | METAP1 | P53582 | 2/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630276 | 0.87 | CYP24A1 (0.70) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL14165623 | 0.86 | CYP24A1 (0.66) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL15617638 | 0.85 | METAP1 (0.70) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL4621871 | 0.85 | CYP24A1 (0.68) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL7590283 | 0.84 | METAP1 (0.78) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL8012038 | 0.84 | METAP1 (0.78) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL9855296 | 0.84 | CYP24A1 (0.63) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| Hydrochloric Acid SCHEMBL10341505 | 0.83 | METAP1 (0.78) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL26063574 | 0.83 | CYP24A1 (0.62) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 | |
| SCHEMBL4621209 | 0.83 | CYP24A1 (0.65) | CYP24A1CYP26A1CYP27A1CYP19A1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139574-A1 | Novel quinoline derivatives | CADILA HEALTHCARE LIMITED | 2008-06-12 | — | — | US | disclosed |
| US-20080139574-A1 | Novel quinoline derivatives | CADILA HEALTHCARE LIMITED | 2008-06-12 | — | — | US | disclosed |
| EP-1927589-A1 | Quinoline derivatives | CADILA HEALTHCARE LTD. (IN) | 2008-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139574-A1 | Novel quinoline derivatives | UGT1A7, CYP3A5, CYP3A7 | CYP24A1 3861/4885CYP26A1 533/4885CYP27A1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.